Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on December 14, 2012. The report discloses material changes regarding executive compensation arrangements effective for the 2013 calendar year.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to executive compensation adjustments:
- Executive Base Salary: Reduced to $1 per year for the Chairman, President, and CEO (Michael Hunkapiller) and the Executive Vice President and CFO (Susan K. Barnes).
- Effective Date: January 1, 2013, through December 31, 2013.
- Bonus Waiver: 100% of bonuses otherwise payable for the 2012 performance period were waived by both executives.
Material Changes Versus Prior Period
The primary material change is the significant reduction in cash compensation for top executives compared to prior periods. While the base salary is reduced to a nominal amount for 2013, the filing specifies that any severance payments triggered by a change of control will be calculated based on the executives' base salaries in effect immediately prior to this reduction, rather than the reduced $1 amount.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The disclosure is strictly limited to the terms of the letter agreements regarding salary reduction and bonus waivers. No unusual items or contingencies outside of these compensation agreements are reported.
Investor Verification Checklist
- Verify the specific base salary amounts for Michael Hunkapiller and Susan K. Barnes prior to December 14, 2012, to quantify the total compensation reduction.
- Review the attached Exhibits 10.1 and 10.2 for the complete legal terms of the letter agreements.
- Confirm whether this salary reduction impacts the company's reported operating expenses in the 2013 fiscal year.
- Check subsequent filings to determine if the executives' compensation was restored or if the $1 salary structure was extended beyond 2013.